Key result
NLR ≤4.4 and troponin T ≤1000 ng/L linked to ~690% greater survival after ICI myocarditis.
Why the study?
ICIM carries high rates of morbidity and death with widely varying clinical outcomes, but little is known about clinical variables associated with long-term survival.
What are the clinical and laboratory predictors of long-term survival in patients with immune checkpoint inhibitor-associated myocarditis?
Population
35 patients diagnosed with ICIM at Massachusetts General Hospital between 2016 and 2022
Comparison
Short-term (<30 days) vs intermediate-term (30–365 days) vs long-term (>365 days) survival groups
Design
Case-control study
Follow-up
Median 8.3 months
Authors
Loading...
NLR ≤4.4 and troponin T ≤1000 ng/L may aid prognosis in ICI-myocarditis; hypothesis-generating pending prospective validation.
Case-Control (n=35)
No
What are the clinical and laboratory predictors of long-term survival in patients with immune checkpoint inhibitor-associated myocarditis?
Effect estimate: HR 7.9
p-value: p=<0.001
Lower peak troponin T, lower neutrophil/lymphocyte ratio, longer interval to ICIM onset, and rapid troponin decrement after immunosuppression predict longer survival in immune checkpoint inhibitor-associated myocarditis.
Dubey et al. (2025) conducted a case-control in Immune checkpoint inhibitor-associated myocarditis (n=35). Clinical and laboratory predictors was evaluated on Long-term survival (>365 days) (HR 7.9, p=<0.001). Long-term survival after immune checkpoint inhibitor-associated myocarditis was independently associated with a neutrophil/lymphocyte ratio ≤4.4 (HR 7.9; P<0.001) and troponin T ≤1000 ng/L.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: